SCCS Preliminary Opinion on Alpha-Arbutin and Beta-Arbutin
Alpha-arbutin and Beta-arbutin are used in cosmetic with antioxidant, bleaching and skin conditioning functions. Following concerns raised during discussion within the Working Group on Cosmetic Products and consequent call for data on these ingredients, the SCCS assessed the safety of Alpha-arbutin and Beta-arbutin in cosmetic products.

ALPHA-ARBUTIN AND BETA-ARBUTIN

Alpha-arbutin and Beta-arbutin (optical isomer) are similar cosmetic ingredients. In cosmetics and personal care products, these ingredients can be used as antioxidants, bleaching and skin conditioning agents. Currently, neither Alpha-arbutin nor Beta-arbutin are regulated under the EU Regulation (EC) Nº 1223/2009 on cosmetic products.

In 2015, the European Commission’s Scientific Committee on Consumer Safety (SCCS) assessed the safety of Alpha-arbutin and Beta-arbutin and published two opinions. The SCCS concluded that the use of Alpha-arbutin up to a concentration of 2% in face creams and 0.5% in body lotions was safe for consumers. Beta-arbutin was considered safe for consumers when used up to a concentration of 7% in face creams and provided that the contamination of hydroquinone in the cosmetic formulations remained below 1 ppm.

The SCCS opinions did not evaluate the potential combined use of hydroquinone releasing substances in cosmetic products.

Discussions within the Working Group on Cosmetic Products raised concerns on hydroquinone content, its release and regarding the aggregate exposure from cosmetic products containing Alpha-arbutin and/or Beta-arbutin. Consequently, a call for data took place and interested parties were asked to provide relevant data/information related to the stability of these ingredients, their dermal absorption, the hydroquinone release rate (including biotransformation) and the aggregate exposure.

NEW SCCS PRELIMINARY OPINION

Last March, the SCCS released its preliminary opinion on the safety of Alpha-arbutin and Beta-arbutin in cosmetic products.

Based on the data provided and relevant information available in the scientific literature, the SCCS stated that it “cannot conclude on the safety of alpha-arbutin when used in face creams up to a maximum concentration of 2% and in body lotions up to a maximum concentration of 0.5%”.

Regarding the use of Beta-arbutin, no information was provided during the call for data and the information available in the scientific literature was insufficient to conclude on the safety of this ingredient.

The Committee considers that lacking data on degradation/metabolism of Alpha-arbutin and Beta-arbutin, exposed to the skin microbiome/enzymes and the release of hydroquinone and its final fate are essential for the safety assessment. Consequently, the SCCS could not recommend a safe concentration for Alpha-arbutin or Beta-arbutin.

The SCCS preliminary opinion is open for comments until 27 May 2022.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Opinion on the safety of alpha-arbutin and beta-arbutin in cosmetic products. SCCS/1642/22. 2022.

further
reading

cosmetic products

Citral under review: SCCS Preliminary Opinion

The SCCS was tasked by the European Commission to evaluate if the safety levels for Citral, determined through QRA2 based on skin sensitization induction, are sufficient to safeguard consumers. A preliminary opinion was released.

Read More »
cosmetic products

Are sunscreens with Benzophenone-4 safe?

Benzophenone-4 is commonly known as a UV-filter in cosmetic products. Learn what the final opinion of SCCS states about Benzophenone’s safety profile as a UV-filter in cosmetic products.

Read More »
cosmetic products

Is Aluminium in cosmetics safe for human health?

The Scientific Committee on Consumer Safety (SCCS) published its Final Opinion on the safety of Aluminium in cosmetic products. This follows a lengthy review process that began in 2013 when the SCCS was first mandated to evaluate the potential health risks of Aluminium (Al) and its compounds in cosmetics.

Read More »
cosmetic products

Silver in Cosmetics: SCCS preliminary opinion.

Ingredients: SILVER

The recent preliminary opinion from the Scientific Committee on Consumer Safety (SCCS) regarding silver in cosmetics is crucial for consumers and manufacturers. This article breaks down the key points, making it easier to understand the implications and stay informed.

Read More »
news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »
cosmetic products

UK proposes ban of wet wipes containing plastic 

The UK has proposed, on April 24, 2024, a regulation titled The Environmental Protection (Wet Wipes Containing Plastic) (England) Regulations 2024, to the World Trade Organization (WTO). The regulation aims to eliminate the supply and sale of plastic-containing wet wipes, including cosmetic ones. The public can offer comments on the draft until June 23, 2024, with adoption expected in September of the same year.

Read More »
news & updates

SCCS preliminary opinion on Citral sensitization endpoint

Ingredients: CITRAL

Date of publication: 27/03/2024

On March 27 2024, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the safety of Citral in cosmetic products. The deadline for comments is set to June 2, 2024.

Read More »
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »